Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CPI-444 + Daratumumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-444||Ciforadenant|V81444|CPI 444|CPI444||Adenosine Targeting 16||Ciforadenant (CPI-444) binds to and inhibits A2A (ADORA2A) on immune cells, which may increase anti-tumor immune response and inhibit tumor growth by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29923026, PMID: 30131376).|
|Daratumumab||Darzalex||JNJ-54767414||CD38 Antibody 7||Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04280328||Phase I||CPI-444 + Daratumumab CPI-444||Study of CPI-444 as a Single Agent and in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma||Recruiting|